{"id":13296,"date":"2024-08-21T16:20:40","date_gmt":"2024-08-21T15:20:40","guid":{"rendered":"https:\/\/cerbaresearch.com\/?post_type=news&p=13296"},"modified":"2024-08-21T16:20:41","modified_gmt":"2024-08-21T15:20:41","slug":"biomarker-assay-driven-clinical-trials","status":"publish","type":"news","link":"https:\/\/staging.cerbaresearch.com\/fr\/news\/biomarker-assay-driven-clinical-trials\/","title":{"rendered":"Biomarker Assay-Driven Clinical Trials"},"content":{"rendered":"
\n

Biomarker assay-driven clinical trials offer researchers a way to gather information on the effects of a drug within an organism that is being studied. <\/p>\n<\/div>\n\n

\n

With their ability to help identify study populations, discover side effects, and track therapeutic response, biomarkers<\/a> can be very useful in clinical trials and drug development. While biomarker development is a long process with several stages, in many trials, using biomarkers can be the key to unlocking disease characteristics. <\/p>\n<\/div>\n\n

\n

Compared to non-biomarker-driven studies, a clinical trial that involves biomarker assays may be enriched by an ability to evaluate therapeutic intervention more effectively, increasing the success of drug development and helping to cut costs.<\/p>\n<\/div>\n\n

\n

This article looks at biomarker strategies and the way biomarker assays are integrated into clinical trials.<\/p>\n<\/div>\n\n

\n

Biomarker Strategies<\/strong><\/h2>\n<\/div>\n\n
\n

Trial investigators wishing to optimize their trials can utilize experienced laboratory service providers to advise and guide them on biomarker strategies. The involvement of a trusted laboratory partner to provide its input on biomarkers from the outset of preclinical stages<\/a> allows trial protocols \u2013 and as a result, trial outcomes – to be optimized.<\/p>\n<\/div>\n\n

\n

Biomarker-Driven Trial Design<\/strong><\/h2>\n<\/div>\n\n
\n

Molecular profiling at the level of individual patients is becoming more affordable and accessible. For this reason, an increasing number of clinical trials are being driven by biomarkers. This allows disease management to be both optimized and personalized. <\/p>\n<\/div>\n\n

\n

Whereas conventional clinical trials focused on evaluating the effect of treatment in populations are defined by histology \u2013 that is, the microscopic study of organs and tissues \u2013 biomarker-driven trial designs demand additional considerations during planning. There are several factors that rely heavily on the nature of the biomarkers themselves, how they are used clinically, and their performance level. Biomarker-driven trials have also led to the requirement of multi-histology and multi-agent master protocols and platform trials, which present their own advantages, as well as operational challenges and limitations, which we will discuss in the following section.<\/p>\n<\/div>\n\n

\n

Mitigating the Limitations of Biomarker Designs<\/h2>\n<\/div>\n\n
\n

While biomarkers can open the door to more personalized disease management, robust methodology is needed for biomarker assay-driven clinical trials, in order to identify participant and treatment groups correctly. <\/p>\n<\/div>\n\n

\n

The \u2018enrichment design\u2019 for biomarker-driven clinical trials randomly assigns biomarker-positive patients to the targeted arm. This design is the most popular, but it can only be recommended when the biomarker predicts the response perfectly. That\u2019s to ensure that biomarker-negative patients aren\u2019t denied a treatment that they would have benefited from otherwise.<\/p>\n<\/div>\n\n

\n

Aside from the enrichment design, there is a substantial number of other designs used in biomarker-driven clinical trials. A review of study designs for clinical trials applied to personalised medicine<\/a> identified 21 trial designs in total, along with 10 subtypes. <\/p>\n<\/div>\n\n

\n

When there is a challenge to answer several clinical research questions in one study, more complex trial designs have emerged, involving separate parts that may constitute individual clinical trials or are characterised by significant prospective adaptations. These complex trial designs include:<\/p>\n<\/div>\n\n

\n